Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide
2. Naldemedine
3. S-297995
4. Symproic
1. Symproic
2. Naldemedine Tosilate
3. Naldemedine Tosylate [usan]
4. Naldemedine (tosylate)
5. V1n8f1rvvo
6. 1345728-04-2
7. Unii-v1n8f1rvvo
8. Symproic (tn)
9. Chembl3039508
10. Schembl20720003
11. Dtxsid10158809
12. Naldemedine Tosylate [mi]
13. Naldemedine Tosylate (jan/usan)
14. Naldemedine Tosilate [jan]
15. Hy-19627a
16. Naldemedine Tosilate [who-dd]
17. Naldemedine Tosylate [orange Book]
18. Cs-0030916
19. D10478
20. Q27291424
21. 17-(cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide 4-methylbenzenesulfonic Acid
22. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5.alpha.)-, 4-methylbenzenesulfonate (1:1)
23. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1)
| Molecular Weight | 742.8 g/mol |
|---|---|
| Molecular Formula | C39H42N4O9S |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 7 |
| Exact Mass | 742.26725010 g/mol |
| Monoisotopic Mass | 742.26725010 g/mol |
| Topological Polar Surface Area | 204 Ų |
| Heavy Atom Count | 53 |
| Formal Charge | 0 |
| Complexity | 1340 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 1 | |
|---|---|
| Drug Name | SYMPROIC |
| Active Ingredient | NALDEMEDINE TOSYLATE |
| Company | SHIONOGI INC (Application Number: N208854. Patents: 9108975, RE46365, RE46375) |
Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
Treatment of opioid-induced constipation (OIC)
A06AH05
API SUPPLIERS
Shandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
NDC Package Code : 53044-002
Start Marketing Date : 2017-03-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Shandong Loncom is an R&D-focused manufacturer of Anti-cancer APIs.
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.
Lead Product(s): Naldemedine Tosylate
Therapeutic Area: Gastroenterology Brand Name: Rizmoic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Shionogi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2020
Lead Product(s) : Naldemedine Tosylate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Shionogi
Deal Size : Not Applicable
Deal Type : Not Applicable
Sandoz Announces Positive NICE Recommendation for Rizmoic® (naldemedine) for OIC
Details : Based on Phase 3 trial data, Rizmoic has been shown to increase the frequency of bowel movements compared to placebo in patients either with cancer or chronic non-cancer pain who had previously received laxative treatment.
Brand Name : Rizmoic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Brand Name : SYMPROIC
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 0.2MG BASE
Packaging :
Approval Date : 2017-03-23
Application Number : 208854
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2026-10-05
US Patent Number : RE46375
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208854
Patent Use Code : U-1185
Delist Requested :
Patent Use Description : TREATMENT OF OPIOID-IN...
Patent Expiration Date : 2026-10-05
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
